Developing a blood marker to monitor womb cancer
Research type
Research Study
Full title
The use of circulating tumour DNA to monitor the activity of womb cancer and predict response to treatment and disease recurrence.
IRAS ID
221907
Contact name
Esther Moss
Contact email
Sponsor organisation
University Hospitals of Leicester
Duration of Study in the UK
4 years, 2 months, 1 days
Research summary
This study aims to investigate whether circulating DNA (cDNA) from womb cancer cells can be used to predict response to treatment and cancer recurrence. Women who have been diagnosed with a high-risk womb cancer or have had a recurrence of their womb cancer and are under active follow up by the oncology team at the University Hospitals of Leicester will be recruited. Information will be recorded on their tumour type, stage at diagnosis, co-morbidities, oncological treatment and current medications. Biopsies taken at their original surgery and any biopsies taken at diagnosis of their cancer recurrence will be analysed to identify if any key genetic mutations are present. A blood sample will be taken from the patient to try and identify ctDNA from the womb cancer cells that may be present in the blood. The presence of any of the genetic mutations seen in the womb cancer biopsies and the acquisition of new mutations in the ctDNA will be compared with the clinical behaviour of the cancer to see whether it is able to indentify response to treatment or disease relapse. Serial blood samples will be taken at the patient’s follow up clinic visits in order to see whether ctDNA can monitor tumour activity.
Semi-structured interviews will also be conducted with a cross-section of the participants to explore their views on using a blood test to follow up of womb cancer.REC name
Wales REC 7
REC reference
17/WA/0342
Date of REC Opinion
20 Oct 2017
REC opinion
Favourable Opinion